Madrigal Pharmaceuticals Stock Price

4.04 (3.13%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Madrigal Pharmaceuticals Inc MDGL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
4.04 3.13% 133.00 19:22:35
Close Price Low Price High Price Open Price Previous Close
132.97 128.3104 133.87 129.40 128.96
Bid Price Ask Price Spread News
132.53 132.90 0.37 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,772 81,882 $ 132.05 $ 10,812,333 155,558 56.82 - 138.59
Last Trade Time Type Quantity Stock Price Currency
16:59:30 formt 100 $ 133.00 USD

Madrigal Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.05B 15.44M 7.91M $ - $ - -5.45 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -1.58M 56.90%

more financials information »

Madrigal Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MDGL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week128.81133.87124.71128.6887,6434.193.25%
1 Month121.55138.59113.76124.62119,91011.459.42%
3 Months105.61138.5998.65115.17133,80427.3925.94%
6 Months92.59138.5979.01110.66146,06740.4143.64%
1 Year91.71138.5956.8296.89169,78741.2945.02%
3 Years45.49325.9838.82137.26215,14487.51192.37%
5 Years8.35325.986.60130.16161,868124.651,492.81%

Madrigal Pharmaceuticals Description

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Your Recent History
Madrigal P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.